Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
48 hedge funds and large institutions have $581M invested in Generation Bio in 2020 Q2 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
61.37% more ownership
Funds ownership: 0% → 61.37% (+61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$164M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$93.1M |
| 3 |
AG
Artal Group
Luxembourg
|
+$62.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$47.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$46.1M |
Top Sellers
GBIO Hedge Fund Activity: Q2 2020 in Review
48 of the 4,889 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2020, worth a combined $581M.
Buyers outnumbered sellers: 48 funds opened new GBIO positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $164M.
- 48 institutional investors held Generation Bio (GBIO) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $581M of Generation Bio stock for Q2 2020.
- 48 funds opened new Generation Bio positions in Q2 2020 and 0 closed out, a net change of +48 holders.
- The largest Generation Bio buyer in Q2 2020 was Fidelity Investments, an estimated $164M added.
Based on aggregated 13F filings for Q2 2020.